Tonix Pharma (TNXP) Acquires Infectious Disease R&D Facility
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Oil market losses easing as nearly 80% of disrupted supply returns, UBS says
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Pre-Open Stock Movers 07/26: (TYME) (MSTR) (FLOW) Higher; (ATIP) (ITRM) (TNXP) Lower (more...)
July 26, 2021 9:29 AM EDTPre-Open Stock Movers:
Tyme Technologies, Inc. (NASDAQ: TYME) 54.6% HIGHER; announced that it has received notification that the United States Patent and Trademark Office has granted additional patent claims related to the Companys metabolomic technology platform. The patent, U.S. Patent No. 11,058,638, involves a targeted delivery of therapeutics to cancer cells.
ATI Physical Therapy (NYSE: ATIP) 41.3% LOWER; reported Q2 revenue of $164 million versus the consensus estimate of $175.37 million. For full year 2021, ATI is now... More
Tonix Pharma (TNXP) Says Interim Analysis Shows TNX-102 SL Unlikely to Demonstrate Statistically Significant Improvement, Enrollment Stopped
July 23, 2021 4:57 PM EDTTonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) has decided to stop enrollment in the Phase 3 RALLY study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the management of fibromyalgia following an unblinded, pre-planned interim analysis by the Independent Data Monitoring Committee (IDMC) of the RALLY study. Based on interim analysis results of the first 50% (n=337) enrolled participants, the IDMC recommended stopping the trial for futility as TNX-102 SL is unlikely to demonstrate a statistically significant improvement in the primary endpoint of overall change from baseline in daily diary pain severity scores between those... More
